By Dan Prochilo ( December 16, 2013, 6:40 PM EST) -- A New Jersey federal judge on Friday barred Mylan Inc. from manufacturing, importing or selling its own version of Teva Pharmaceutical Industries Ltd.'s brand-name treatment for Parkinson's disease, Azilect, for more than three years, after the generic-drug maker stipulated its proposed generic infringed a Teva patent....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.